These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 34201655)

  • 1. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
    Dhatchinamoorthy K; Colbert JD; Rock KL
    Front Immunol; 2021; 12():636568. PubMed ID: 33767702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immune escape: MHC expression in primary tumours versus metastases.
    Garrido F; Aptsiauri N
    Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class I antigens and immune surveillance in transformed cells.
    Aptsiauri N; Cabrera T; Garcia-Lora A; Lopez-Nevot MA; Ruiz-Cabello F; Garrido F
    Int Rev Cytol; 2007; 256():139-89. PubMed ID: 17241907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour MHC class I downregulation and immunotherapy (Review).
    Bubeník J
    Oncol Rep; 2003; 10(6):2005-8. PubMed ID: 14534734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC heterogeneity and response of metastases to immunotherapy.
    Algarra I; Garrido F; Garcia-Lora AM
    Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
    Cheng WF; Hung CF; Lee CN; Su YN; Chang MC; He L; Wu TC; Chen CA; Hsieh CY
    Eur J Immunol; 2004 Jul; 34(7):1892-900. PubMed ID: 15214037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class I down-regulation: tumour escape from immune surveillance? (review).
    Bubeník J
    Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
    Humphreys RE; Hillman GG; von Hofe E; Xu M
    Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
    Garrido F; Cabrera T; Aptsiauri N
    Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade.
    Sato Y; Bolzenius JK; Eteleeb AM; Su X; Maher CA; Sehn JK; Arora VK
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
    Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
    Marijt KA; Doorduijn EM; van Hall T
    Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.